Ars Technica
Ars Technica
US · 30 mins ago

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

The vaccine reportedly thwarted the cancer's return and spread.
Ars Technica
Do you trust Ars Technica?
Sign in to rate
Discussion
?

No comments yet — be the first to start the discussion!